Vical Introduces RapidResponse DNA Vaccine Cell-Free Platform

Vical Incorporated has announced the RapidResponse(TM) DNA vaccine platform designed to produce large quantities of vaccine in a matter of days, compared with the several months required for conventional vaccine production.

RapidResponse DNA vaccine manufacturing involves a cell-free process and single-step vaccine purification.

This platform is intended to significantly reduce the time required to develop, manufacture and deploy vaccines against emerging diseases during the early stages of an infectious outbreak.